Insider Selling: BioNTech (NASDAQ:BNTX) CEO Sells 36,000 Shares of Stock

by · The Markets Daily

BioNTech SE Sponsored ADR (NASDAQ:BNTX – Get Free Report) CEO Ugur Sahin sold 36,000 shares of BioNTech stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $97.78, for a total value of $3,520,080.00. Following the completion of the transaction, the chief executive officer directly owned 708,709 shares in the company, valued at $69,297,566.02. This trade represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

  • On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total value of $3,670,400.00.
  • On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total value of $3,260,880.00.
  • On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Trading Down 0.5%

Shares of NASDAQ BNTX traded down $0.53 during mid-day trading on Wednesday, hitting $98.13. The stock had a trading volume of 706,871 shares, compared to its average volume of 1,112,188. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00. The business has a 50 day moving average price of $96.94 and a two-hundred day moving average price of $95.55. The firm has a market cap of $24.82 billion, a P/E ratio of -12.53 and a beta of 1.29.

BioNTech (NASDAQ:BNTX – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company’s quarterly revenue was down 59.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.60) earnings per share. On average, equities analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Several institutional investors and hedge funds have recently modified their holdings of BNTX. Larson Financial Group LLC boosted its stake in shares of BioNTech by 86.4% during the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares in the last quarter. EFG International AG purchased a new position in shares of BioNTech during the fourth quarter valued at about $29,000. Caitong International Asset Management Co. Ltd raised its stake in BioNTech by 520.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $30,000 after buying an additional 260 shares in the last quarter. Integrated Wealth Concepts LLC bought a new position in BioNTech in the second quarter worth about $39,000. Finally, Tower Research Capital LLC TRC lifted its holdings in BioNTech by 118.2% in the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after buying an additional 305 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Jefferies Financial Group reiterated a “buy” rating on shares of BioNTech in a report on Monday, June 1st. Citigroup reduced their price target on BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. Morgan Stanley lowered their price target on BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a research report on Wednesday, July 8th. Berenberg Bank dropped their price objective on BioNTech from $155.00 to $140.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. Finally, UBS Group upgraded BioNTech from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $117.00 to $135.00 in a research report on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $126.00.

View Our Latest Report on BNTX

BioNTech Company Profile

(Get Free Report)

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

See Also